Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm study of UGN-102 in intermediate-risk low-grade non-muscle-invasive bladder cancer
2021-005948-29Phase 3Active
- Sponsor
- UroGen Pharma
- Start
- Feb 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zusduri in non-muscle-invasive bladder cancer (NMIBC) and bladder cancer, sponsored by UroGen Pharma. Primary endpoint: Complete Response Rate. Started Feb 2022; status: active.
02
Drugs
zusduri
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)bladder cancer
Beyond the preview
Go deeper on 2021-005948-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005948-29.